logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Neurogenic Detrusor Overactivity

    FiltersReset Filters
    6 results

    • botox

      (onabotulinumtoxinA)
      Allergan, Inc.
      Usage: BOTOX is indicated for treating overactive bladder, detrusor overactivity in adults and pediatric patients, chronic migraines, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, and blepharospasm/strabismus. It is prescribed for patients unresponsive to or intolerant of anticholinergic medications. Limitations in efficacy for specific conditions are noted.

    • myrbetriq

      (mirabegron)
      Astellas Pharma US, Inc.
      Usage: MYRBETRIQ is indicated for treating adult overactive bladder (OAB) symptoms, including urge urinary incontinence, urgency, and urinary frequency, either alone or with solifenacin succinate. It is also indicated for pediatric patients (ages 3+) with neurogenic detrusor overactivity (NDO) who weigh 35 kg or more.

    • oxybutynin chloride

      (OXYBUTYNIN CHLORIDE)
      Chartwell RX, LLC
      Usage: Oxybutynin chloride extended-release tablets are indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency. They are also approved for pediatric patients aged 6 and older with detrusor overactivity linked to neurological conditions, such as spina bifida.

    • oxybutynin chloride

      (Oxybutynin Chloride)
      Ajanta Pharma USA Inc.
      Usage: Oxybutynin chloride is indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency. It is also approved for pediatric patients aged 6 and older with detrusor overactivity related to neurological conditions, such as spina bifida.

    • oxybutynin chloride

      (Oxybutynin Chloride)
      Advagen Pharma Limited
      Usage: Oxybutynin chloride is indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency. It is also approved for pediatric patients aged 6 and older with detrusor overactivity associated with neurological conditions such as spina bifida.

    • oxybutynin chloride

      (oxybutynin chloride)
      Accord Healthcare, Inc.
      Usage: Oxybutynin chloride extended-release tablets are indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency. They are also indicated for pediatric patients aged 6 and older with detrusor overactivity related to neurological conditions.